JP2025516359A - テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 - Google Patents

テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 Download PDF

Info

Publication number
JP2025516359A
JP2025516359A JP2024565274A JP2024565274A JP2025516359A JP 2025516359 A JP2025516359 A JP 2025516359A JP 2024565274 A JP2024565274 A JP 2024565274A JP 2024565274 A JP2024565274 A JP 2024565274A JP 2025516359 A JP2025516359 A JP 2025516359A
Authority
JP
Japan
Prior art keywords
cancer
compound
compound according
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516359A5 (https=
Inventor
エヴァン ジェイ． ホーン
ジョシュア ディー． ハンセン
マシュー ディー． アレクサンダー
フェイ ホアン
マーク エー． ナジー
Original Assignee
ツリーライン バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツリーライン バイオサイエンシズ インコーポレイテッド filed Critical ツリーライン バイオサイエンシズ インコーポレイテッド
Publication of JP2025516359A publication Critical patent/JP2025516359A/ja
Publication of JP2025516359A5 publication Critical patent/JP2025516359A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024565274A 2022-05-06 2023-05-04 テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 Pending JP2025516359A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263339308P 2022-05-06 2022-05-06
US63/339,308 2022-05-06
US202263398752P 2022-08-17 2022-08-17
US63/398,752 2022-08-17
US202263429834P 2022-12-02 2022-12-02
US63/429,834 2022-12-02
US202363449728P 2023-03-03 2023-03-03
US63/449,728 2023-03-03
US202363454486P 2023-03-24 2023-03-24
US63/454,486 2023-03-24
PCT/US2023/020956 WO2023215449A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Publications (2)

Publication Number Publication Date
JP2025516359A true JP2025516359A (ja) 2025-05-27
JP2025516359A5 JP2025516359A5 (https=) 2026-05-01

Family

ID=86609470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565274A Pending JP2025516359A (ja) 2022-05-06 2023-05-04 テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤

Country Status (7)

Country Link
US (1) US20250288683A1 (https=)
EP (1) EP4519272A1 (https=)
JP (1) JP2025516359A (https=)
AU (1) AU2023264537A1 (https=)
CA (1) CA3252016A1 (https=)
MX (1) MX2024013312A (https=)
WO (1) WO2023215449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4401729A4 (en) * 2021-09-17 2025-10-01 Kymera Therapeutics Inc BCL-XL DEGRADING AGENTS AND THEIR USES
WO2025036119A1 (zh) * 2023-08-11 2025-02-20 北京三秀生物医药科技有限公司 靶向Bcl-xL蛋白的PROTAC及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
EP3743069B1 (en) 2018-01-22 2025-08-06 BioVentures, LLC Bcl-2 proteins degraders for cancer treatment
WO2020163823A2 (en) 2019-02-08 2020-08-13 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
WO2021007307A1 (en) 2019-07-10 2021-01-14 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
WO2021078301A1 (zh) 2019-10-24 2021-04-29 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
AU2021207672A1 (en) 2020-01-15 2022-07-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
MX2022010512A (es) 2020-04-28 2022-11-16 Recurium Ip Holdings Llc Inhibidores de proteína bcl-2.
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
EP4401729A4 (en) 2021-09-17 2025-10-01 Kymera Therapeutics Inc BCL-XL DEGRADING AGENTS AND THEIR USES

Also Published As

Publication number Publication date
US20250288683A1 (en) 2025-09-18
CA3252016A1 (en) 2023-11-09
WO2023215449A1 (en) 2023-11-09
MX2024013312A (es) 2025-02-10
AU2023264537A1 (en) 2024-11-14
EP4519272A1 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
KR102533599B1 (ko) 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
TWI736566B (zh) Ｔｌｒ７/８拮抗劑及其用途
IL324078A (en) Fused ring compounds
KR20200135846A (ko) 인자 XIIa 억제제
JP2025516358A (ja) テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤
WO2023215482A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
JP2025516359A (ja) テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤
WO2024153240A1 (zh) 一种杂环化合物及其制备方法和应用
CN112638376B (zh) 取代的四氢环戊二烯并[c]吡咯、取代的二氢吡咯嗪、其类似物和其使用方法
CN121013856A (zh) Egfr降解剂、其药物组合物及其用途
WO2017025493A1 (en) Quinoline ezh2 inhibitors
KR20220077140A (ko) 프로스타글란딘 e2(pge2) ep4 수용체 길항제
WO2025059245A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
KR102831634B1 (ko) Mlkl 결합 또는 분해용 화합물 및 이들의 의약 용도
TW202337500A (zh) 抗體結合的化學降解誘導物及其方法
KR20250023483A (ko) 퀴놀론 bcl6 이작용성 분해제
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101575A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025191185A1 (en) Azine-based compounds as par-2 inhibitors and therapeutic uses thereof